You may have noticed light brown skin patches, freckling in unusual places, or small bumps along nerves—and wondered what could connect them. NF1 (neurofibromatosis type 1) is a genetic condition that causes changes in skin pigment and the growth of tumors on nerves and other tissues, and it can affect learning, bone development, and long-term health.
This article What Is NF1 Disease will help you understand how NF1 develops, how clinicians diagnose it, and what treatment and monitoring options exist so you can make informed decisions about care. Expect clear explanations about symptoms, genetic causes, and practical steps for management.
Understanding NF1 Disease
NF1 affects skin, peripheral nerves, and bones through benign tumor growth, pigment changes, and variable developmental issues. It is caused by mutations in the NF1 gene and can be inherited or occur spontaneously.
What Is Neurofibromatosis Type 1?
Neurofibromatosis type 1 (NF1) is a genetic disorder that primarily leads to growth of benign nerve-sheath tumors called neurofibromas. These tumors can appear on or under the skin and along peripheral nerves, and they vary widely in number and size between individuals.
You will commonly see skin findings such as multiple café-au-lait spots and freckling in the armpits or groin. Other possible features include Lisch nodules (small pigmented spots) on the iris and skeletal changes like scoliosis or tibial dysplasia. Age of onset is usually in childhood, and severity ranges from mild cosmetic issues to complications affecting function and quality of life.
Symptoms and Clinical Features
Symptoms vary, so your care must be personalized. Common skin signs include six or more café-au-lait macules (>5 mm in children, >15 mm in adults) and small neurofibromas that may increase during puberty or pregnancy. Plexiform neurofibromas represent deeper, often larger nerve tumors that can cause pain, disfigurement, or nerve dysfunction.
Neurologic and developmental effects include learning disabilities, attention deficits, and increased risk of optic pathway gliomas that can affect vision. Musculoskeletal problems such as scoliosis, bone bowing, and short stature occur in a subset of patients. Malignant transformation of neurofibromas is rare but possible; watch for rapid growth, new pain, or neurologic decline.
Causes and Genetics
NF1 results from pathogenic variants in the NF1 gene on chromosome 17, which encodes neurofibromin, a protein that helps regulate cell growth. Loss of neurofibromin function increases Ras pathway signaling, promoting tumor formation. About 50% of cases are inherited in an autosomal dominant pattern; the other 50% arise from de novo mutations in a person with no affected parent.
If you have NF1, each child has a 50% chance of inheriting the altered gene. Genetic testing can identify NF1 mutations to confirm diagnosis, guide family planning, and help access surveillance recommendations tailored to your specific mutation and clinical picture.
NF1 Diagnosis and Treatment
You will learn how clinicians confirm NF1, the main treatment options available, and how ongoing care reduces complications and supports daily function.
How NF1 Is Diagnosed
Diagnosis combines clinical exam, family history, and targeted testing. A clinician looks for diagnostic signs such as six or more café-au-lait macules (≥5 mm in children, ≥15 mm in adults), two or more neurofibromas or one plexiform neurofibroma, freckling in the armpit or groin, optic pathway glioma, Lisch nodules on eye exam, distinctive bone lesions, or a first-degree relative with NF1.
Genetic testing of the NF1 gene can confirm the diagnosis when clinical signs are unclear or for family planning. Imaging (MRI) evaluates internal or optic nerve tumors. You may undergo ophthalmology, dermatology, and neurology assessments to document baseline function and detect complications early.
Current Treatment Options
Treatment targets specific problems rather than curing the underlying gene mutation. For symptomatic tumors, surgery removes or debulks growths that cause pain, neurological deficits, or disfigurement. Complete resection may not be possible for plexiform neurofibromas.
Medication options include targeted therapies such as MEK inhibitors for inoperable plexiform neurofibromas; these can shrink tumors and reduce symptoms. Pain management, anticonvulsants for seizures, and physical therapy address functional issues. Radiation is generally avoided for benign NF1 tumors unless absolutely necessary because of secondary tumor risk. Treatment plans are individualized by tumor type, location, age, and symptom severity.
Ongoing Management and Care
You need lifelong surveillance because NF1 manifestations change over time. Standard follow-up includes annual physical exams, skin and neurologic checks, and periodic MRI for symptomatic or high-risk lesions. Children require extra monitoring for developmental delays, learning disabilities, and optic pathway gliomas.
Multidisciplinary care teams—genetics, neurosurgery, dermatology, ophthalmology, orthopedics, pain specialists, and education support—coordinate interventions. Genetic counseling informs family planning and recurrence risk. Keep a personal record of exams, imaging, and treatments to streamline care across specialists.